Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Marc Schneider

Independent Medical Examiner Fort Myers, FL Medical Doctor

NPI 1679573869 CMS profile 167010

12751 S Cleveland Ave, Suite 102, Fort Myers, FL 33907

Open in the dashboard

General payments

$10,961

73 records reported · program years 2019–2025

Research payments

$250

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Marc Schneider of Fort Myers, FL is reported in the CMS Open Payments database as having received $10,961 across 73 general payments and $250 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $317 7
2024 General $54 3
2023 General $128 6
2022 General $478 14
2021 General $148 3
2020 General $1,775 17
2020 Research $250 1
2019 General $8,062 23

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Marc Schneider
  • Independent Medical Examiner median
  • Middle half of Independent Medical Examiner
  • National median

In program year 2019, general payments to Marc Schneider were reported at $8,062. Among 21 Independent Medical Examiner profiles paid that year, the median was $113 and the middle half received between $25 and $528.

Show as a table
Year Marc Schneider Independent Medical Examiner median Middle half National median
2019 $8,062 $113 $25–$528 $163
2020 $1,775 — — $114
2021 $148 — — $132
2022 $478 — — $149
2023 $128 — — $160
2024 $54 — — $164
2025 $317 — — $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Allergan Inc. $7,448 26 payments
  2. Medtronic Vascular, Inc. $2,206 18 payments
  3. Merz North America, Inc. $391 6 payments
  4. Apyx Medical Corporation $258 2 payments
  5. AbbVie, Inc. $194 9 payments
  6. Motiva USA, LLC $186 2 payments
  7. Mentor Worldwide LLC $110 4 payments
  8. Galderma Laboratories, L.P. $56 3 payments
  9. Davol Inc. $55 1 payment
  10. Clozex Medical Inc $32 1 payment
  11. Other $26 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Gift $6,750 5 payments
  2. Food and Beverage $2,906 64 payments
  3. Travel and Lodging $1,306 4 payments
Products named General payments · program years 2019–2025
  1. NATRELLE $7,249 15 payments
  2. CoreValve Evolut $1,443 12 payments
  3. Motiva Implant Matrix $186 2 payments
  4. NATRELLE SALINE-FILLED BREAST IMPLANTS Plastic Surgery $78 4 payments
  5. NATRELLE SALINE-FILLED BREAST IMPLANTS Plastics $70 5 payments
  6. BOTOX $69 3 payments
  7. BOTOX COSMETIC $64 3 payments
  8. Xeomin $64 2 payments
  9. MemoryGel Breast Implants $59 2 payments
  10. Phasix Mesh $55 1 payment
  11. Other $108 4 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Sientra, Inc. $250 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

75

Prescriptions dispensed, refills included

Drug cost

$337

Paid at the pharmacy, in all

Branded share of claims

85.3%

Brand-name drugs, not generics

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 24 $160
Methocarbamol Generic 11 $62
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 16 $59
Ondansetron Odt Ondansetron Brand 24 $56

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $20
$20 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

74 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Independent Medical Examiner in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record